January 22, 2018
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Argos Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-222414 Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Argos Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-222414) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on January 24, 2018, or as soon thereafter as practicable.
Very truly yours,
Argos Therapeutics, Inc.
| By: | /s/ Lori R. Harrelson | |
| Name: | Lori R. Harrelson | |
| Title: | Vice President of Finance |
